Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.47 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16809391 | 0.85 | GCK (0.47) | GCKPTGER1HTTMAOBCYP1A2 | |
| SCHEMBL25385270 | 0.84 | CCR5 (0.46) | MAOBCCR5RAB9ASMN1; SMN2 | |
| SCHEMBL30574868 | 0.84 | CCR5 (0.46) | MAOBCCR5RAB9ASMN1; SMN2 | |
| SCHEMBL2436153 | 0.81 | GCK (0.49) | GCKUSP28USP25PTGER1HTT | |
| SCHEMBL1577749 | 0.81 | GCK (0.51) | GCKUSP28USP25HTTMAOB | |
| SCHEMBL6246737 | 0.81 | NPC1 (0.43) | HTTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL26223542 | 0.80 | GCK (0.50) | GCKMAOBSLC6A4CCR5RAB9A | |
| SCHEMBL9955235 | 0.79 | GCK (0.50) | GCKHTTMAOBSLC6A4CCR5 | |
| SCHEMBL2661187 | 0.78 | GCK (0.52) | GCKHTTMAOBSLC6A4CCR5 | |
| SCHEMBL16926498 | 0.78 | GCK (0.55) | GCKPTGER1HTTMAOBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018537-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-8536176-B2 | GPR119 agonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20110137032-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2311822-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018537-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GCK 2066/4885USP28 3286/4885USP25 404/4885 |
| US-20110137032-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GCK 2066/4885USP28 3286/4885USP25 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.